Quality is one of four performance categories under the Merit-based Incentive Payment System (MIPS). For the 2026 performance year under Traditional MIPS, to fully participate in the Quality performance category, you or your group need to report on:
- Six quality measures, one of which is required to be an outcome measure, if available. If an outcome measure is not available, then you have to submit a high priority measure. You or your group would also have to meet the data completeness requirement (report 100% of eligible encounters and provide answers for at least 75%) for each measure submitted.
- Submit a complete specialty measure set if the specialty measure set contains less than 6 measures.
Eligible clinicians can report less than 6 measures, or without an Outcome/High Priority Measure and be eligible for the full Quality incentive through the Eligible Measures Applicability (EMA) Process.
Which collection types are eligible for EMA?
The EMA process is only applied to the following collection types :
- MIPS clinical quality measures (MIPS CQMs) (formerly referred to as “Registry measures”);
- Medicare Part B claims measures (only available for small practices)
CMS doesn't apply the EMA process to Qualified Clinical Data Registry (QCDR) measures or eCQMs collected in Certified Electronic Health Record Technology (CEHRT) because the clinical relationship pattern analysis (previously known as cluster analysis) either doesn’t apply or can’t be done within the current QCDR or CEHRT certification requirements.
If you submit any QCDR measures or eCQMs, alone or in combination with Medicare Part B claims measures or MIPS CQMs, you are expected to submit 6 quality measures.
The EMA process:
- Uses a clinical relations test to see if you could have submitted more measures, including outcome and high priority measures
- Adjusts the scoring to accurately reflect how the clinical relations test affected your or your group’s performance
To learn more about the EMA analysis and how it affects your quality performance calculation and score, see:
- 2025 EMA and Denominator Reduction User Guide (PDF)
- 2026 EMA and Denominator Reduction User Guide (PDF)
EMA’s practical effect when you submit less than 6 quality measures:
For example, a clinician reporting the Anesthesiology clinically related quality measures (404, 430 and 463) through a registry could score up to 30 points. Those 30 points are usually compared with a quality score target of 60 based on the required 6 measures (i.e. 10 points x 6 measures = 60 points). Under EMA, the quality performance category score is then re-weighted from 30 points to 60 points so the MIPS score for the clinician is not negatively impacted.
If the clinician also has zero eligible instances for measure 463 in the EMA cluster, measure #463 will be submitted to 0/0 and the 3 remaining anesthesiology measures will be re-weighted to 60 MIPS points. The maximum points available for each measure with a perfect performance rate (based on CMS published benchmarks) are shown in parenthesis. Measures without max points currently do not have historical benchmarks. Scores, based on performance for non-benchmarked measures, will be calculated post submission.
These are the 2026 sets of MIPS registry measures that get the score adjusted by EMA:
Anesthesiology Care
- #404 Anesthesiology Smoking Abstinence (10 point maximum)
- #430 Prevention of Post-Operative Nausea and Vomiting (PONV) – Combination Therapy (flat benchmark, up to 10 points)
- #463 Prevention of Post-Operative Vomiting (POV) – Combination Therapy (Pediatrics) (flat benchmark, up to 10 points)
CABG Care
- #164 Coronary Artery Bypass Graft (CABG): Prolonged Intubation (no historical benchmark)
- #167 Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure (no historical benchmark)
- #168 Coronary Artery Bypass Graft (CABG): Surgical Re-Exploration (no historical benchmark)
- #445 Risk-Adjusted Operative Mortality for Coronary Artery Bypass Graft (CABG) (no historical benchmark)
Cataract Care
- #191 Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery (7 point cap)
- #303 Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (no historical benchmark)
- #304 Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery (no historical benchmark)
- #389 Cataract Surgery: Difference Between Planned and Final Refraction (no historical benchmark)
Computed Tomography
- #360 Optimizing Patient Exposure to Ionizing Radiation: Count of Potential High Dose Radiation Imaging Studies: Computed Tomography (CT) and Cardiac Nuclear Medicine Studies (flat benchmark, up to 10 points)
- #364 Optimizing Patient Exposure to Ionizing Radiation: Appropriateness: Follow-up CT Imaging for Incidentally Detected Pulmonary Nodules According to Recommended Guidelines (flat benchmark, up to 10 points)
- #405 Appropriate Follow-up Imaging for Incidental Abdominal Lesions (flat benchmark, up to 10 points)
- #406 Appropriate Follow-up Imaging for Incidental Thyroid Nodules in Patients (up to 10 points)
Diagnostic Imaging
- #145 Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy (7 point cap)
Endoscopy and Polyp Surveillance
Infectious Disease Inpatient (New for 2026)
- #065 Appropriate Treatment for Upper Respiratory Infection (URI) (7 point cap)
- #066 Appropriate Testing for Pharyngitis (7 point cap)
- #130 Documentation of Current Medications in the Medical Record (7 point cap)
Interventional Radiology
- #145 Radiology: Exposure Dose Indices or Exposure Time and Number of Images Reported for Procedures Using Fluoroscopy (7 point cap)
- #413 Door to Puncture Time for Endovascular Stroke Treatment (no historical benchmark)
- #465 Uterine Artery Embolization Technique: Documentation of Angiographic Endpoints and Interrogation of Ovarian Arteries (no historical benchmark)
Pathology 1
- #249: Barrett’s Esophagus 250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #395 Lung Cancer Reporting (Biopsy/Cytology Specimens) (flat benchmark, up to 10 points)
- #396 Lung Cancer Reporting (Resection Specimens) (flat benchmark, up to 10 points)
- #397 Melanoma Reporting (flat benchmark, up to 10 points)
Pathology 2
- #249: Barrett’s Esophagus 250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #395 Lung Cancer Reporting (Biopsy/Cytology Specimens) (flat benchmark, up to 10 points)
- #397 Melanoma Reporting (flat benchmark, up to 10 points)
- #491 Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma (up to 10 points)
Pathology 3
- #249: Barrett’s Esophagus 250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #395 Lung Cancer Reporting (Biopsy/Cytology Specimens) (flat benchmark, up to 10 points)
- #396 Lung Cancer Reporting (Resection Specimens) (flat benchmark, up to 10 points)
- #491 Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma (up to 10 points)
Pathology 4
- #249: Barrett’s Esophagus 250: Radical Prostatectomy Pathology Reporting (flat benchmark, up to 10 points)
- #397 Melanoma Reporting (flat benchmark, up to 10 points)
- #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician (flat benchmark, up to 10 points)
Pathology – Skin Cancer
- #397 Melanoma Reporting (flat benchmark, up to 10 points)
- #440: Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician (flat benchmark, up to 10 points)
Surgical Care
- #355 Unplanned Reoperation within the 30 Day Postoperative Period (10 point maximum)
- #357 Surgical Site Infection (SSI) (10 point maximum)
- #358 Patient-Centered Surgical Risk Assessment and Communication (7 point cap)
2026 Specialty Measure Sets with Fewer than 6 Measures
The following specialty measure sets have fewer than 6 MIPS CQM measures available. These sets are eligible for the EMA denominator reduction process when reporting via MIPS CQMs. For the complete list including Medicare Part B claims-only specialties, refer to the 2026 EMA and Denominator Reduction User Guide.
(C) = change to measures available; (N) = newly identified as having fewer than 6 measures
Anesthesiology (C)
MIPS CQMs: #404 (10 point maximum), #430 (flat benchmark, up to 10 points), #463 (flat benchmark, up to 10 points), #477 (flat benchmark, up to 10 points)
Diagnostic Radiology
MIPS CQMs: #145 (7 point cap), #360 (flat benchmark, up to 10 points), #364 (flat benchmark, up to 10 points), #405 (flat benchmark, up to 10 points), #406 (up to 10 points)
Electrophysiology
MIPS CQMs: #392 (no historical benchmark), #393 (no historical benchmark)
Hospitalists
MIPS CQMs: #005 (7 point cap), #008 (7 point cap), #047 (7 point cap), #130 (7 point cap)
Optometry
MIPS CQMs: #117 (7 point cap), #130 (7 point cap), #226 (7 point cap), #238 (7 point cap), #374 (7 point cap)
Radiation Oncology (C)
MIPS CQMs: #102 (no historical benchmark), #143 (flat benchmark, up to 10 points), #144 (flat benchmark, up to 10 points), #226 (7 point cap)
Please note: You should submit all quality measures that apply to your scope of practice and not limit your submission to those measures contained within the clinical topic. For the complete 2026 EMA clinical topics and specialty measure sets, refer to the 2026 EMA and Denominator Reduction User Guide. The EMA process was established to support clinicians and groups who may not have 6 quality measures available for, and applicable, to their practice.